Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome-Reference-Cited by-同舟云学术

Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome

Published:2017-02-14 Issue:5 Volume:32 Page:739-749
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Mov Disord.

Author:

Hill-Burns Erin M.¹,Debelius Justine W.²,Morton James T.³,Wissemann William T.¹,Lewis Matthew R.¹,Wallen Zachary D.¹,Peddada Shyamal D.⁴,Factor Stewart A.⁵,Molho Eric⁶,Zabetian Cyrus P.⁷^ORCID,Knight Rob²³⁸,Payami Haydeh¹⁹

Affiliation:

1. Department of Neurology; University of Alabama at Birmingham; Birmingham Alabama USA

2. Department of Pediatrics; University of California San Diego; La Jolla California USA

3. Department of Computer Science and Engineering; University of California San Diego; La Jolla California USA

4. Biostatistics and Computational Biology Branch; National Institute of Environmental Health Sciences; Research Triangle Park North Carolina USA

5. Department of Neurology; Emory University School of Medicine; Atlanta Georgia USA

6. Department of Neurology; Albany Medical College; Albany New York USA

7. Veterans Affairs Puget Sound Health Care System and Department of Neurology; University of Washington; Seattle Washington USA

8. Center for Microbiome Innovation; University of California San Diego; La Jolla California USA

9. Center for Genomic Medicine; HudsonAlpha Institute for Biotechnology; Huntsville Alabama USA

Funder

National Institute of Neurological Disorders and Stroke

Udall

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Reference54 articles.

1. Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms;Cersosimo;J Neurol,2013

2. Neuropathological basis of nonmotor manifestations of Parkinson's disease;Adler;Mov Disord,2016

3. Colonic inflammation in Parkinson's disease;Devos;Neurobiol Dis,2013

4. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease;Forsyth;PLoS One,2011

5. Vagotomy and subsequent risk of Parkinson's disease;Svensson;Ann Neurol,2015

Cited by 680 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The gut microbiota–oligodendrocyte axis: A promising pathway for modulating oligodendrocyte homeostasis and demyelination-associated disorders;Life Sciences;2024-10

2. Difference in gut microbial dysbiotic patterns between body-first and brain-first Parkinson's disease;Neurobiology of Disease;2024-10

3. Disrupted gut harmony in attention-deficit/hyperactivity disorder: Dysbiosis and decreased short-chain fatty acids;Brain, Behavior, & Immunity - Health;2024-10

4. Role of the Gut Microbiome and Bacterial Amyloids in the Development of Synucleinopathies (Review);Биохимия;2024-09-14

5. The role of gut-derived short-chain fatty acids in Parkinson's disease;Neurogenetics;2024-09-13